Pancreatic Cholera (W.D.H.A. syndrome)

1975 ◽  
Vol 367 (1) ◽  
pp. 35-45 ◽  
Author(s):  
Jean-Claude Rambaud ◽  
Annie Galian ◽  
Jacques Scotto ◽  
Pierre Hautefeuille ◽  
Claude Matuchansky ◽  
...  
Keyword(s):  
Pancreatic Cholera

Increased Tear Secretion in a Patient with Pancreatic Cholera

Cornea ◽  
1987 ◽  
Vol 6 (1) ◽  
pp. 61
Author(s):  
J. P. Gilbard ◽  
D. A. Dartt ◽  
S. R. Rossi ◽  
K. L. Gray ◽  
R. P. Rood ◽  
...  
Keyword(s):  
Tear Secretion ◽  
Pancreatic Cholera

Effect of a Long-Acting Somatostatin Analogue (SMS 201–995) in a Patient with Pancreatic Cholera

1985 ◽  
Vol 312 (1) ◽  
pp. 17-21 ◽  
Author(s):  
Paul N. Maton ◽  
Thomas M. O'Dorisio ◽  
Brent A. Howe ◽  
Katherine E. McArthur ◽  
John M. Howard ◽  
...  
Keyword(s):  
Somatostatin Analogue ◽  
Pancreatic Cholera ◽  
Long Acting

SUCCESSFUL TREATMENT OF THERAPY-RESISTANT PANCREATIC CHOLERA WITH HUMAN LEUCOCYTE INTERFERON

The Lancet ◽  
1985 ◽  
Vol 325 (8431) ◽  
pp. 725-727 ◽  
Author(s):  
K. Öberg ◽  
H. Lindström ◽  
G. Alm ◽  
G. Lundqvist
Keyword(s):  
Successful Treatment ◽  
Pancreatic Cholera

Pancreatic Cholera Syndrome

2009 ◽  
pp. 1563-1563
Author(s):  
Markus Braun-Falco ◽  
Henry J. Mankin ◽  
Sharon L. Wenger ◽  
Markus Braun-Falco ◽  
Stephan DiSean Kendall ◽  
...  
Keyword(s):  
Pancreatic Cholera

Pancreatic Cholera

2007 ◽  
Vol 102 ◽  
pp. S183
Author(s):  
Gushyalatha Boya ◽  
Purna C. Kashyap ◽  
Rami Hawari ◽  
Rondon Helbert ◽  
Willaim H. Nealon
Keyword(s):  
Pancreatic Cholera

PANCREATIC CHOLERA DUE TO PRODUCTION OF GASTRIC INHIBITORY POLYPEPTIDE

The Lancet ◽  
1972 ◽  
Vol 300 (7781) ◽  
pp. 791-793 ◽  
Author(s):  
E. Elias ◽  
S.R. Bloom ◽  
R.B. Welbourn ◽  
M. Kuzio ◽  
JuliaM. Polak ◽  
...  
Keyword(s):  
Gastric Inhibitory Polypeptide ◽  
Pancreatic Cholera

VIPomas

2011 ◽  
pp. 924-928
Author(s):  
Katie Wynne
Keyword(s):  
Vasoactive Intestinal Polypeptide ◽  
Islet Cell ◽  
Human Subjects ◽  
Cell Tumour ◽  
Watery Diarrhoea ◽  
Elevated Plasma ◽  
Healthy Human ◽  
Islet Cell Tumour ◽  
Secretory Diarrhoea ◽  
Pancreatic Cholera

Vasoactive intestinal polypeptide (VIP) secreting tumours are rare neuroendocrine tumours. The associated syndrome was first described by Priest and Alexander in 1957. They reported a case that they thought to be a variant of the Zollinger–Ellison syndrome—a patient with an islet cell tumour associated with diarrhoea, peptic ulceration, and hypokalaemia (1). The following year, Verner and Morrison described a syndrome of profuse, refractory, watery diarrhoea with severe hypokalaemia and dehydration associated with a non-β‎-cell islet cell tumour (2). Historical terms for this syndrome have included ‘pancreatic cholera’ (as the diarrhoea is similar to the secretory diarrhoea observed in cholera) and the acronym WDHA (watery diarrhoea, hypokalaemia, and achlorhydria). However, these terms are inaccurate descriptions of a syndrome that can be associated with both extrapancreatic tumours and normal gastric acid secretion. In 1973, Bloom first connected the watery diarrhoea with an elevated plasma VIP level and an increased tumour content of VIP, suggesting the term ‘VIPoma syndrome’ (3). There followed a debate as to whether VIP was a marker for the syndrome or the causative agent for the diarrhoea. However, in 1983, Kane infused porcine VIP intravenously in healthy human subjects, achieving VIP levels similar to patients with VIPomas. Profuse watery diarrhoea developed within 4 h of infusion, providing evidence that VIP was indeed the mediator of the syndrome (4).

Sign in / Sign up

Export Citation Format

Share Document